Illinois Municipal Retirement Fund Has $4.41 Million Position in Glaukos Co. (NYSE:GKOS)

Illinois Municipal Retirement Fund lifted its holdings in Glaukos Co. (NYSE:GKOS) by 5.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 29,418 shares of the medical instruments supplier’s stock after acquiring an additional 1,556 shares during the period. Illinois Municipal Retirement Fund owned approximately 0.05% of Glaukos worth $4,411,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Creative Planning increased its holdings in Glaukos by 64.1% in the third quarter. Creative Planning now owns 12,643 shares of the medical instruments supplier’s stock worth $1,647,000 after purchasing an additional 4,937 shares in the last quarter. State of Alaska Department of Revenue grew its position in shares of Glaukos by 6.0% during the 3rd quarter. State of Alaska Department of Revenue now owns 31,357 shares of the medical instruments supplier’s stock worth $4,085,000 after buying an additional 1,785 shares during the period. New York State Teachers Retirement System increased its stake in shares of Glaukos by 0.4% in the 3rd quarter. New York State Teachers Retirement System now owns 48,143 shares of the medical instruments supplier’s stock valued at $6,272,000 after acquiring an additional 200 shares in the last quarter. Amalgamated Bank increased its stake in shares of Glaukos by 4.5% in the 3rd quarter. Amalgamated Bank now owns 15,926 shares of the medical instruments supplier’s stock valued at $2,075,000 after acquiring an additional 679 shares in the last quarter. Finally, Crossmark Global Holdings Inc. lifted its position in shares of Glaukos by 15.8% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 4,051 shares of the medical instruments supplier’s stock valued at $527,000 after acquiring an additional 554 shares during the period. 99.04% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have commented on GKOS. Morgan Stanley cut shares of Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price target for the company. in a report on Monday, December 2nd. Stephens upgraded Glaukos to a “strong-buy” rating in a research note on Monday, December 2nd. Mizuho raised Glaukos from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $140.00 to $200.00 in a research report on Wednesday, February 19th. BTIG Research increased their price target on Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Finally, Citigroup upgraded Glaukos from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $132.00 to $162.00 in a report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $163.25.

Glaukos Trading Down 0.1 %

Shares of Glaukos stock opened at $120.35 on Thursday. The company has a market capitalization of $6.64 billion, a P/E ratio of -41.93 and a beta of 1.04. The stock has a fifty day simple moving average of $151.35 and a 200 day simple moving average of $139.46. Glaukos Co. has a 12-month low of $83.90 and a 12-month high of $163.71. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS) last posted its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The firm had revenue of $105.50 million during the quarter, compared to the consensus estimate of $100.72 million. On average, sell-side analysts anticipate that Glaukos Co. will post -1.08 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Glaukos news, Director Gilbert H. Kliman sold 2,000 shares of the business’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $144.01, for a total value of $288,020.00. Following the transaction, the director now owns 32,336 shares of the company’s stock, valued at approximately $4,656,707.36. The trade was a 5.82 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Tomas Navratil sold 3,416 shares of the firm’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the sale, the insider now directly owns 72,437 shares of the company’s stock, valued at approximately $10,658,380.18. This represents a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 18,744 shares of company stock valued at $2,792,151. Corporate insiders own 6.40% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.